nafamostat has been researched along with Cardiac Rupture, Post-Infarction in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ihno, T | 1 |
| Nakagawa, T | 1 |
| Furukawa, H | 1 |
| Shimizu, K | 1 |
| Egi, K | 1 |
| Maemura, T | 1 |
| Motomiya, T | 1 |
1 other study available for nafamostat and Cardiac Rupture, Post-Infarction
| Article | Year |
|---|---|
Various problems during long-term percutaneous cardiopulmonary support.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Benzamidines; Blood Transfusion, Autologous; Cardiop | 1997 |